A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Banda, Dominic HPerin, Paula M
Brown, Richard J P
Todt, Daniel

Solodenko, Wladimir
Hoffmeyer, Patrick
Kumar Sahu, Kamlesh
Houghton, Michael
Meuleman, Philip
Müller, Rolf

Kirschning, Andreas
Pietschmann, Thomas
Issue Date
2019-06-01
Metadata
Show full item recordCitation
J Hepatol. 2019 Jun;70(6):1082-1092. doi: 10.1016/j.jhep.2019.01.033. Epub 2019 Feb 13.Affiliation
TWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.Publisher
ElsevierJournal
Journal of HepatologyPubMed ID
30769006Type
ArticleLanguage
enISSN
1600-0641ae974a485f413a2113503eed53cd6c53
10.1016/j.jhep.2019.01.033
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.
- Authors: Perin PM, Haid S, Brown RJ, Doerrbecker J, Schulze K, Zeilinger C, von Schaewen M, Heller B, Vercauteren K, Luxenburger E, Baktash YM, Vondran FW, Speerstra S, Awadh A, Mukhtarov F, Schang LM, Kirschning A, Müller R, Guzman CA, Kaderali L, Randall G, Meuleman P, Ploss A, Pietschmann T
- Issue date: 2016 Jan
- Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1.
- Authors: Hu Z, Rolt A, Hu X, Ma CD, Le DJ, Park SB, Houghton M, Southall N, Anderson DE, Talley DC, Lloyd JR, Marugan JC, Liang TJ
- Issue date: 2020 Jul 16
- Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
- Authors: Vausselin T, Séron K, Lavie M, Mesalam AA, Lemasson M, Belouzard S, Fénéant L, Danneels A, Rouillé Y, Cocquerel L, Foquet L, Rosenberg AR, Wychowski C, Meuleman P, Melnyk P, Dubuisson J
- Issue date: 2016 Oct 1
- A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.
- Authors: Lee M, Yang J, Jo E, Lee JY, Kim HY, Bartenschlager R, Shin EC, Bae YS, Windisch MP
- Issue date: 2017 Mar 23
- Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
- Authors: Calland N, Sahuc ME, Belouzard S, Pène V, Bonnafous P, Mesalam AA, Deloison G, Descamps V, Sahpaz S, Wychowski C, Lambert O, Brodin P, Duverlie G, Meuleman P, Rosenberg AR, Dubuisson J, Rouillé Y, Séron K
- Issue date: 2015 Oct